Literature DB >> 1686641

Ammonia-induced alterations in glutamate and muscimol binding to cerebellar synaptic membranes.

V L Rao1, A K Agrawal, C R Murthy.   

Abstract

Binding of glutamate and muscimol (an agonist for GABAA receptors) to their respective receptors has been studied in the cerebellum of normal and hyperammonemic rats. There was a decrease in both high- and low-affinity binding of glutamate in the cerebellum during hyperammonemia. Kinetic studies revealed that the decrease is due to a reduction in the number of binding sites, but not due to changes in the binding affinities. Further studies also revealed that the decrease was only in the N-methyl-D-aspartate (NMDA)-specific binding sites without any alterations in the binding to non-NMDA sites represented by kianic acid (KA)- and quisqualic acid (QQ)-sensitive receptor sites. These effects were also mimicked when the membrane preparations from the cerebellum of normal animals were incubated with ammonium acetate. Enhancement of muscimol binding was observed in animals injected with ammonium acetate. It is concluded that hyperammonemic states, even in the presence of a functional liver, are capable of altering amino acid neurotransmission and this might play an important role in cerebral dysfunction under these conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686641     DOI: 10.1016/0304-3940(91)90408-l

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Ammonia-induced alterations in the metabolism of glutamate and aspartate in neuronal perikarya and synaptosomes of rat cerebellum.

Authors:  V L Rao; C R Murthy
Journal:  Metab Brain Dis       Date:  1992-03       Impact factor: 3.584

Review 2.  Glutamatergic synaptic dysfunction in hyperammonemic syndromes.

Authors:  V L Rao; C R Murthy; R F Butterworth
Journal:  Metab Brain Dis       Date:  1992-03       Impact factor: 3.584

Review 3.  Is ammonia a pathogenetic factor in Alzheimer's disease?

Authors:  N Seiler
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

4.  Tissue-specific alterations of binding sites for peripheral-type benzodiazepine receptor ligand [3H]PK11195 in rats following portacaval anastomosis.

Authors:  V L Rao; R Audet; G Therrien; R F Butterworth
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

Review 5.  Effects of hyperammonemia and liver failure on glutamatergic neurotransmission.

Authors:  Pilar Monfort; María-Dolores Muñoz; Amina ElAyadi; Elena Kosenko; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

6.  Loss of [3H]MK801 binding sites in brain in congenital ornithine transcarbamylase deficiency.

Authors:  L Ratnakumari; I A Qureshi; R F Butterworth
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

7.  Binding of the ligand [3H]MK-801 to the MK-801 binding site of the N-methyl-D-aspartate receptor during experimental encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit.

Authors:  R J de Knegt; J Kornhuber; S W Schalm; K Rusche; P Riederer; J Tan
Journal:  Metab Brain Dis       Date:  1993-06       Impact factor: 3.584

8.  Neurochemical effects of L-pyroglutamic acid.

Authors:  C F de Mello; D D De La Vega; L T Pizutti; F P Lopes; M A Rubin; J G Homerich; C R Melo; J E Somer; D O Souza; M Wajner
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

9.  Ammonium acetate inhibits ionotropic receptors and differentially affects metabotropic receptors for glutamate.

Authors:  G Lombardi; G Mannaioni; P Leonardi; G Cherici; V Carlà; F Moroni
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Pharmacologic rescue of hyperammonemia-induced toxicity in zebrafish by inhibition of ornithine aminotransferase.

Authors:  Matthias Zielonka; Maximilian Breuer; Jürgen Günther Okun; Matthias Carl; Georg Friedrich Hoffmann; Stefan Kölker
Journal:  PLoS One       Date:  2018-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.